Among patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), Tagrisso (osimertinib) was associated with a higher incidence of cancer therapy-related cardiac side effects (CTRCEs) compared with other EGFR tyrosine …

… References 1. US National Cancer Institute: Surveillance Epidemiology and End … 13, 2025 3. US National Cancer Institute. SEER*Explorer. https:… 2025 4. US National Cancer Institute. Non-small cell … metastatic-non-small-cell-lung-cancer/. Accessed January …

Today is World Cancer Day. And, it becomes even more important to raise awareness about lung cancer - one of the most prevalent forms of the disease. A recent study has found a rise in lung cancer cases among individuals who have never smoked. ALSO READ |  …

Becker’s is proud to recognize 70 outstanding chief strategy officers leading hospitals and health systems in 2024. These visionary leaders help brand, market and expand their organizations, developing strategies that propel progress. They play a pivotal …

Evergrande has been involved in restructuring negotiations after racking up $300 billion in liabilities in the wake of Beijing's crackdown on excessive debt and rampant speculation in the real estate sector - Copyright AFP Noel Celis The U.S. National …

Onc.AI, a digital health company developing AI-driven oncology clinical management solutions using Deep Learning imaging AI, today announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Device Designation for its “Serial CTRS” …

Generations ago, cancer was thought to be an inevitable disease. Either you were going to get it, or you weren’t, and there wasn’t anything you could do about it. Decades of scientific research, however, proves there are certain actions we can take to …

On World Cancer Day 2025, global biopharmaceutical leader AstraZeneca renewed its pledge to tackle Africa’s growing cancer crisis, emphasizing early detection, cutting-edge technology, and equitable care under the theme “United by Unique.” ‘ The campaign …

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023. "Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance …

Cancer immunotherapies. Heart valve replacements. Drugs for diabetes, depression, arthritis, heart disease. Every day, millions of ordinary Americans benefit from these and other medical treatments made possible through research funded by the National …